One in 5 of the highest-revenue drugs of 2022 was exclusively approved for rare conditions, accounting for more than 7% of US pharmaceutical spending.
Benjamin N. Rome, MD, MPH
Advertisement
Articles by Benjamin N. Rome, MD, MPH
Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US.
Advertisement
Latest Updated Articles
US Spending on High-Revenue Rare Disease Drugs in 2022Published: November 14th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform
2
FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads
3
Catchment Areas Shape Diversity and Access in Oncology Trials: Amir Fathi, MD
4
Overcoming Mistrust in Clinical Trial Enrollment Through Community Resources: Susan Vadaparampil, PhD, MPH
5